Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48546 | 0.85 | ALDH1A1 (0.37) | MEN1KMT2AGAAKDM4EPKM | |
| SCHEMBL48598 | 0.78 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL1786529 | 0.76 | PIK3CD (0.63) | KDM4EPKMRCE1PIK3CGPIK3CA | |
| SCHEMBL48627 | 0.73 | PIK3CD (0.51) | KDM4EPKMRCE1PIK3CGPIK3CA | |
| SCHEMBL1891948 | 0.72 | NOS1 (0.45) | MEN1KMT2AGAAKDM4EPIK3CG | |
| Bromide SCHEMBL1885215 | 0.71 | NOS1 (0.43) | MEN1KMT2AGAAKDM4EPIK3CG | |
| SCHEMBL26479577 | 0.70 | KDM4E (0.49) | MEN1KMT2AGAAKDM4EPKM | |
| SCHEMBL28357165 | 0.69 | SMN1; SMN2 (0.55) | MEN1KMT2AGAAKDM4EPKM | |
| SCHEMBL29099561 | 0.69 | PIK3CG (0.46) | KDM4EPKMRCE1PIK3CGPIK3CA | |
| SCHEMBL30185562 | 0.69 | PIK3CG (0.46) | KDM4EPKMRCE1PIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | MEN1 2238/4885KMT2A 2183/4885GAA 2233/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | MEN1 2238/4885KMT2A 2183/4885GAA 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.